By Josh White
Date: Monday 18 Mar 2024
(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients who had failed prior hypomethylating agent (HMA) treatment.
By Josh White
Date: Wednesday 13 Mar 2024
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.
By Josh White
Date: Monday 04 Mar 2024
(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.
Currency | UK Pounds |
Share Price | 137.50p |
Change Today | -2.50p |
% Change | -1.79 % |
52 Week High | 350.00 |
52 Week Low | 125.00 |
Volume | 40,251 |
Shares Issued | 68.81m |
Market Cap | £94.61m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 1 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
14:16 | 10 @ 135.00p |
14:16 | 208 @ 140.00p |
14:16 | 54 @ 135.00p |
11:46 | 25,000 @ 137.59p |
13:20 | 7 @ 137.00p |
You are here: research